TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01596764
Drug: Placebo of MNTX and NLX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
Study: NCT03238911
Drug: Iron isomaltoside/ferric derisomaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).
Study: NCT00268138
Drug: elmex gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elmex gel once a week
Study: NCT03256552
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation Aerosol
Study: NCT01670357
Drug: DA-6034 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study: NCT01670357
Drug: DA-6034 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study: NCT01670357
Drug: DA-6034 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study: NCT02203812
Drug: Probiotic Arm
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
Study: NCT02203812
Drug: Placebo Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
Study: NCT02259933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01404091
Drug: LY2940094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04355962
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
Study: NCT04488705
Drug: ETD002 - single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of ETD002
Study: NCT04488705
Drug: Placebo - single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo
Study: NCT04488705
Drug: Placebo - 7 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of Placebo for 7 days
Study: NCT04488705
Drug: Placebo - 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of Placebo for 14 days
Study: NCT02884089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01452412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be taken on the same schedule as the active arm
Study: NCT00793767
Drug: placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v
Study: NCT01358227
Drug: PR104
Normalized name: PR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
Study: NCT01465464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet was administered orally twice per day after meals, morning and evening.
Study: NCT00000403
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03458130
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonactive control
Study: NCT02505633
Drug: lidocaine mixed with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
Study: NCT00547703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
Study: NCT03495882
Drug: AGEN1884 + AGEN2034
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGEN1884 + AGEN2034 according to protocol design
Study: NCT01443247
Drug: anti-d
Normalized name: D-Gam Anti-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
Study: NCT00437684
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/50 mg 2 cpr bid monotherapy
Study: NCT01590407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01528241
Drug: ABP688
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Study: NCT02375672
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion
Study: NCT05430828
Drug: Repatha (evolocumab); Praluent (alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Injection
Study: NCT00632554
Drug: prednisolone 0.5 mg/kg/day for three months
Approvals — FDA: no, EMA: no, PMDA: no
Description: period of treatment
Study: NCT00632554
Drug: prednisolone 0.5 mg/kg/day for six months
Approvals — FDA: no, EMA: no, PMDA: no
Description: period of therapy
Study: NCT00565279
Drug: ASF1057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, topical
Study: NCT00565279
Drug: ASF1057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, Topical
Study: NCT00409383
Drug: Genasense® (oblimersen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
Study: NCT00409383
Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
Study: NCT00409383
Drug: Temodar® (temozolomide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
Study: NCT04683185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6742-matched placebo tablets.
Study: NCT03718611
Drug: BR9001
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR9001 is a test drug as generic
Study: NCT03718611
Drug: BR900A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR900A is a reference drug
Study: NCT02109328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets
Study: NCT04010942
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT00738972
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg pravastatin. Duration: 12 months. Tablets
Study: NCT00738972
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg simvastatin. Duration: 12 months. Tablets
Study: NCT00738972
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Study: NCT01281748
Drug: intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
Study: NCT00006125
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00838565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion on three consecutive months
Study: NCT01974193
Drug: Floseal
Normalized name: Floseal Hemostatic Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of floseal on intervention arm
Study: NCT02815228
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
Study: NCT01822132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control
Study: NCT03794037
Drug: dydrgesterone 10 mg( tab)/12hs/14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
Study: NCT03748199
Drug: POL6014
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)
Study: NCT03748199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally at a dose and frequency matched to POL6014
Study: NCT00882258
Drug: 12.5 mg Proellex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg Proellex administered orally daily
Study: NCT00882258
Drug: 25 mg Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Proellex administered orally daily
Study: NCT00882258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily
Study: NCT03152370
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00218517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules using blue 00 capsules
Study: NCT03207243
Drug: GSK3772847
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
Study: NCT03533387
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Study: NCT02803918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01800617
Drug: Liothyronine, Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02702401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.90% w/v sodium chloride IV infusion
Study: NCT02608112
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
Study: NCT03207243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
Study: NCT00677807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study: NCT01336686
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for 4 weeks
Study: NCT01686646
Drug: paracetamol + caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol with caffeine
Study: NCT00501202
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 4 weeks
Study: NCT04019041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 mL pre-filled syringe
Study: NCT04664504
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
Study: NCT04664504
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
Study: NCT02776228
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
Study: NCT01388842
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Study: NCT01388842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Study: NCT00991419
Drug: [18F]AZD4694
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
Study: NCT01032135
Drug: medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for naltrexone
Study: NCT02362165
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/d,once-weekly,per oral.
Study: NCT02362165
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9mg/㎡,d1-4
Study: NCT01693328
Drug: PecFent® (fentanyl) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03126097
Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
Study: NCT03126097
Drug: COCP Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
Study: NCT00945503
Drug: GSK1018921
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1018921 is a GT1 recepor antagonist
Study: NCT06074107
Drug: BEBT-908 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
Study: NCT02411331
Drug: Ethanol 40% + Enoxaparine 400UI/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03087201
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: analogous to experimental intervention
Study: NCT00699972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Study: NCT04623164
Drug: Cocktail from complex phytoadaptogens (CFA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
Study: NCT02188368
Drug: POM
Normalized name: Ipomea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188368
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188368
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188368
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02710604
Drug: CMX157
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02487108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
Study: NCT02978287
Drug: BAVU Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue preservation solution for transplantation
Study: NCT02881996
Drug: IV tylenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tylenol given scheduled in addition to standard PCA
Study: NCT02881996
Drug: No IV tylenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional IV Tylenol given
Study: NCT02881996
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: both groups receive as part of our standard postop pain protocol after all operations
Study: NCT03611569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - concentrate for solution for infusion, single dose
Study: NCT00419562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule designed to match active drug
Study: NCT01095588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets
Study: NCT02250209
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles.
Study: NCT02244203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01127503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were identically matched to Metyrosine.
Study: NCT01921829
Drug: Protocolized Diuretic Strategy
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide).
Study: NCT01715818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching aleglitazar placebo tablet orally daily
Study: NCT01024543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03646721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
Study: NCT01466270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00839293
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once, see arm description for more information
Study: NCT02361528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneously, for 5 days
Study: NCT02365636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
Study: NCT06161792
Drug: 0.8 mg RCN3028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06161792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02866838
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT01697657
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study: NCT00826267
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
Study: NCT02623803
Drug: Placebo D5W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04066426
Drug: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.